Lilly Plans $5 Billion Biologics Plant in Virginia

Eli Lilly, a leading global pharmaceutical company, has announced a massive $5 billion investment to build an advanced biologics manufacturing facility in Goochland County, Virginia. The plant will specialize in producing bioconjugates and monoclonal antibodies, critical components in innovative treatments for various diseases. This development is expected to create 650 permanent, high-skill jobs in manufacturing and research, while also generating approximately 1,800 construction jobs during the building phase. The sprawling campus will include cutting-edge manufacturing units and laboratory spaces designed to meet the growing demand for biologics. Set to become operational later this decade, the facility underscores Lilly’s long-term commitment to U.S.-based innovation. “This investment not only strengthens our manufacturing capabilities but also creates high-quality jobs, boosts local economies, and advances healthcare for Americans nationwide,” said David A. Ricks, Lilly’s CEO.